Corcept Therapeutics (CORT) Invested Capital (2016 - 2025)
Historic Invested Capital for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $631.9 million.
- Corcept Therapeutics' Invested Capital fell 108.53% to $631.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $631.9 million, marking a year-over-year decrease of 108.53%. This contributed to the annual value of $679.6 million for FY2024, which is 3411.93% up from last year.
- Per Corcept Therapeutics' latest filing, its Invested Capital stood at $631.9 million for Q3 2025, which was down 108.53% from $635.8 million recorded in Q2 2025.
- Corcept Therapeutics' Invested Capital's 5-year high stood at $683.3 million during Q1 2025, with a 5-year trough of $375.8 million in Q4 2021.
- For the 5-year period, Corcept Therapeutics' Invested Capital averaged around $532.0 million, with its median value being $522.7 million (2021).
- Its Invested Capital has fluctuated over the past 5 years, first plummeted by 2819.06% in 2021, then skyrocketed by 4141.92% in 2024.
- Quarter analysis of 5 years shows Corcept Therapeutics' Invested Capital stood at $375.8 million in 2021, then surged by 33.54% to $501.8 million in 2022, then rose by 0.97% to $506.7 million in 2023, then surged by 34.12% to $679.6 million in 2024, then decreased by 7.02% to $631.9 million in 2025.
- Its Invested Capital stands at $631.9 million for Q3 2025, versus $635.8 million for Q2 2025 and $683.3 million for Q1 2025.